ALL is the commonest cancer of childhood and treatment related toxicity and relapse are important therapeutic challenges. To further improve outcome new, non-toxic, targeted therapies need to be developed. These may be targeted to the leukaemic population in general or to the sub-population thought to give rise to relapse. Relapsed disease is characterised by an increased involvement of sites other than the bone marrow. This has led to the suggestion that chemo-resistance and invasion may be linked.
Grant Award – Kidscan PhD Studentship (2012- 2015)
Funding Award – £65,000
Funding Awarded To – Professor Vaskar Saha
Research Location – University of Manchester
Lead Researcher – Professor Vaskar Saha